[Myocardial function and the use of propranolol in ischemic heart disease].
Clinical-functional analysis of the efficacy of propranolol was conducted in 32 patients with ischemic heart disease and stable angina pectoris (with angiographically verified stenosing coronary atherosclerosis) depending on the initial myocardial contractility. A marked antianginal effect of propranolol in a dose of up to 160 mg daily was demonstrated irrespective of the initial myocardial contractile function. Treatment with propranolol was not attended with signs of cardiac insufficiency or aggravation of its subclinical symptoms. The results of the study provide convincing data that optimum doses of blocking agents of beta-adrenergic receptors of the myocardium causing a negative inotropic effect even in patients with diminished myocardial function may be used more widely.
D000328:Adult; D000368:Aged; D002302:Cardiac Output / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D003864:Depression, Chemical; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects*; D011433:Propranolol / Q000627:therapeutic use*
D011433:Propranolol
Funktsional'noe sostoianie miokarda i primenenie propranolola pri ishemicheskoĭ bolezni serdtsa.